Mumbai: Drugmaker Ipca Laboratories Ltd is in talks with Ranbaxy Laboratories Ltd to widen the scope of their existing tie-up for sales in US to include more drugs and to extend it to cover Canada, a top official said.
India’s top drugmaker Ranbaxy had agreed to sell 22 drugs manufactured by Ipca in the US, of which six are expected to be launched this fiscal, executive director A.K. Jain told Reuters in an interview on Wednesday.
“It will be a large list of drugs ... much bigger than the list that we currently have,” Jain said. “Hopefully this year it should be finalized.”
“Over three years, each of these products will have 10% market share,” Jain said forecasting revenue of about Rs2.5 billion from the US in three years.